Durham biotech treating wartime patients in Ukraine moves closer to FDA submission


A Durham biotech is moving closer to commercializing technology that's currently treating people injured in the war in Ukraine.

Previous What's next for Charlotte fintech startup Infinant after closing $5M in funding
Next Construction contract to help turn Austin hotels into housing for the homeless questioned